Literature DB >> 6691899

A bioassay for cyclophosphamide in blood, lung and tumour.

A C Begg, K A Smith.   

Abstract

A bioassay has been developed to detect and quantify the concentration of cytotoxic metabolites of cyclophosphamide (CY) in blood, tumour, and lungs of mice. Extracts were made of blood or solid tissues taken from mice given CY and these were used to treat log phase Chinese Hamster V79 cells in culture for up to 24 h. The amount of cell killing was tested by colony formation 7 days later. The effects of incubation time, CY dose, and the time of tissue sampling after CY injection were investigated. The bioassay could detect cytotoxic metabolites in blood after doses as low as 10 mg kg-1 CY given i.p. The half life of these metabolites in blood after giving 400 mg kg-1 i.p. decreased over a 2 h period from 14 to 9 min. The method was then modified to define the pharmacokinetics of CY metabolites in two different types of tumour and in lung. The half life of the cytotoxic metabolites in the lung was longer than in blood, falling from 35 to 11 min over a 2 h period. In tumours, the half lives were longer again, i.e. approximately 61 min. The maximum metabolite levels achieved were similar in the two tumour types, although these differed markedly in their therapeutic response to CY. The bioassay for CY is a relatively simple and rapid procedure, and the extension of its application from body fluids to solid tissues makes it a useful tool in experimental pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6691899      PMCID: PMC1976679          DOI: 10.1038/bjc.1984.8

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  Stem-cell survival and tumor control in the Lewis lung carcinoma.

Authors:  G G Steel; K Adams
Journal:  Cancer Res       Date:  1975-06       Impact factor: 12.701

2.  Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds.

Authors:  N Brock
Journal:  Cancer Treat Rep       Date:  1976-04

3.  Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans.

Authors:  C Fenselau; M N Kan; S S Rao; A Myles; O M Friedman; M Colvin
Journal:  Cancer Res       Date:  1977-08       Impact factor: 12.701

4.  Microsomal activation of cyclophosphamide in vivo.

Authors:  T A Connors; P L Grover; A M McLoughlin
Journal:  Biochem Pharmacol       Date:  1970-04       Impact factor: 5.858

5.  Metabolism of cyclophosphamide by rat hepatic microsomes.

Authors:  N E Sladek
Journal:  Cancer Res       Date:  1971-06       Impact factor: 12.701

6.  Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo.

Authors:  N E Sladek
Journal:  Cancer Res       Date:  1973-06       Impact factor: 12.701

7.  Tissue culture cytotoxicity assay for cyclophosphamide metabolites in rat body fluids.

Authors:  F A Weaver; A R Torkelson; W A Zygmunt; H P Browder
Journal:  J Pharm Sci       Date:  1978-07       Impact factor: 3.534

8.  Metabolism of cyclophosphamide.

Authors:  N Brock; H J Hohorst
Journal:  Cancer       Date:  1967-05       Impact factor: 6.860

9.  The enzymatic basis of the selective action of cyclophosphamide.

Authors:  P J Cox; B J Phillips; P Thomas
Journal:  Cancer Res       Date:  1975-12       Impact factor: 12.701

10.  In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU.

Authors:  I F Tannock
Journal:  Br J Cancer       Date:  1980-12       Impact factor: 7.640

View more
  3 in total

1.  Responses of a murine B16 melanoma to pharmacotherapy studied and compared with different assay systems.

Authors:  Y Kuwashima; O Matsubara; T Kasuga
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

2.  Thermochemotherapy-induced resistance to cyclophosphamide.

Authors:  M Urano; J Kahn; L A Kenton
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640

3.  Tumour response to chemotherapy in animals that have been treated with the same drugs prior to tumour implantation: a model for studying host effects on apparent drug resistance.

Authors:  C K Luk; I F Tannock
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.